

Index to Volume Twenty-nine

Index of Issues: January, 1-64; February, 65-120; March, 121-188; April, 189-252; May, 253-310; June, 311-372; July, 373-426; August, 427-496; September, 497-558; October, 559-622; November, 623-736; December, 737-856.

INDEX OF AUTHORS

- A**
Aavitsland P, 222
Abdullah ASM, 360
A C, 201
Achilles SL, 655
Adam MB, 811
Adler N, 756
Agbalika F, 698
Ahdieh L, 427
Aklilu M, 175
Alary M, 324
Aleström A, 828
Allen-Taylor L, 436
Alpers MP, 265
Alvarenga IC, 157
Alvarez S, 752
Alves AC, 157
Anagonou S, 324
Anang J, 265
Anastos K, 427
Anderson JE, 643
Andreoni M, 665
Aral SK, 6
Aral SO, 6, 133, 453, 530, 798
Argent S, 216
Ashley R, 253, 559
Ashton MR, 246
Asp A-K, 379
Avonts D, 426
- B**
Babona D, 265
Bain RM, 259
Bakker R, 228
Ballereau F, 624
Bascom T, 373
Bauer HM, 411
Bauwens JE, 253
Beidinger HA, 271
Beksinska ME, 32
Belloni DR, 628
Benfield C, 216
Benson DA, 465
Berglund T, 25
Béria JU, 536
Berman S, 6, 144, 285
Beyene A, 175
Bishai D, 83
Bitoungui DM, 637
Bjune G, 828
Blank S, 465
Bloomfield PJ, 294
Boardman L, 288
Boer K, 710
Boireaux C, 376
Bolan G, 144, 411
Bong CTH, 114
Booth S, 780
Borthagaray G, 792
Bourne N, 597
Branson BM, 38
Branzuela A, 373
Braverman P, 678
Bretl DA, 331
Bricard-Pacaud V, 624
Brown DR, 763
Brown NL, 678
- Brown-Peterside P, 406
Brunelle B, 789
Bryant JH, 79
Buatiang A, 668
Buku L, 216
Burk RD, 182, 427
Burstein GR, 737
Bwayo J, 106
- C**
Cabada MM, 510
Campbell D, 294
Campos-Outcalt D, 119, 372
Campos PE, 559
Carballo-Díéguez A, 465
Casin I, 353
Castle PE, 182
Castrucci BC, 417
Cates W Jr, 168, 350
Catlin M, 559
Celentano DD, 201, 366
Cenedella C, 752
Champion JD, 520
Chan RKKW, 311
Chen JL, 277
Chen S, 647
Chiasson MA, 406
Chin V, 678
Chiphangwi JD, 366
Clarke JG, 288
Clark KL, 1
Clark LR, 436
Clayton JL, 144
Clementson C, 216
Cobb BK, 20
Cohen DA, 737
Cole BF, 628
Cone R, 253, 655
Connolly CA, 721
Cook RL, 246
Copley M, 216
Corey L, 399
Creinin MD, 112
Cromwell PF, 391
Crosby RA, 20, 387, 503, 552
Crowe SR, 576
Cullen AP, 576
Cu-Uvin S, 427
- D**
Dai X, 242
Danilenko NV, 376
Darwin LH, 576
Davies SL, 20, 387, 503
Davis G, 399
Dean J, 216
Debattista J, 216
Decena CU, 465
de la Salmonière P, 353, 698
De Lister MB, 559
Denekens J, 426
De Panfilis G, 121
Deperthes B, 32
De Quiñones MR, 559
Detels R, 335
De Vlas SJ, 228
Dias F, 157
- DiClemente RJ, 20, 387, 503
Dillner J, 207
Dillon J-AR, 792
DiSpigno M, 752
Dodge B, 552
Dolezal C, 465
Dong Z, 212
Dorlencourt F, 376
Dorrucci M, 665
Douglas JM Jr, 65, 196
Downey L, 100
Dudley KL, 597
Duerr A, 427
Duncan LT, 628
Dwyer J, 216
- E**
Eche A, 353
Echevarría JJ, 510
Egesah OB, 444
Eis-Hübinger AM, 637
Ellen J, 397
Ellen JM, 756
Elliott L, 840
- F**
Falconi I, 624
Farley TA, 144, 150
Farley TP, 769
Fielding R, 360
Fields MC, 483
Finelli L, 769
Fischer L, 259, 373
Fisman DN, 608
Fitch JT, 811
Flahault A, 319
Flanigan TP, 752
Fonck K, 106
Fontanet AL, 175
Ford K, 13, 50
Fortenberry D, 144
Foster M, 196, 491
Foxman B, 133
Fredlund H, 25
Freedman DO, 510
Frost E, 157
- G**
Galama JMD, 710
Gao X, 212
Garland SM, 647
Garnett GP, 818
Gaustad P, 828
Gaydos CA, 1, 271
Gaydos JC, 1
Gaytant MA, 710
Geisler WM, 189
Geraldo N, 324
Ghidini A, 121
Gibson JJ, 769
Gibson P, 411
Gift TL, 542, 703
Gisser JM, 483
Glass AG, 182
Golden MR, 472
Goldie SJ, 608
Gomez MP, 253, 259
- Gorbach PM, 453
Gotuzzo E, 510
Gouws E, 44
Go VF, 201
Graham CA, 552
Graifemberghi S, 121
Grandry B, 353
Greenblatt RM, 427
Gregson S, 568
Grewal N, 674
Grillner L, 379
Groen J, 710
Guédou A, 324
Gurvey JE, 756
- H**
Habbema JDF, 228, 444
Haddix A, 542
Hager WD, 811
Haikala O, 746
Hanbrook L, 294
Handsfield HH, 144
Harezlak J, 114
Harper DM, 628
Harrington K, 20, 387, 503
Harwell JJ, 752
Hasbun J, 559
Hayashi M, 79
Hayes R, 228
Heber W, 288
Hedley AJ, 360
Heffelfinger JD, 285
Hennessy M, 92
Henriksson L, 379
Hernandez M, 411
Hillier SL, 288, 581
Hillis SE, 144
Hiltunen-Back E, 746
Hinwood G, 216
Holden AEC, 520
Holmes KK, 133, 253, 259, 453, 559
Holt R, 406
Hook EW III, 20, 387, 486, 503, 608
Hoover DR, 366
Horta BL, 536
Howell MR, 1, 83
Hunt K, 417
Hurwitz S, 119, 372
Hutchins K, 834
Hwang L-Y, 769
- I**
Irwin KL, 542, 703
Italian Seroconversion Study Group, 665
- J**
Jackson M, 436
Jaffar S, 157
Jail STD Prevalence Monitoring Group, 834
Janier M, 353, 698
Jappe U, 533
Joly JR, 324
Joyner JL, 196

Judson FN, 65, 196

K

Kahle B, 533
 Kahn RH, 150, 285
 Kallings I, 207
 Kamb ML, 417
 Karim SSA, 721
 Kassler WJ, 703
 Katz BP, 114
 Kent C, 144, 294, 373, 411, 422
 Kerndt PR, 277
 Kilmarx PH, 668
 Kimball A-M, 259
 Kimoto K, 79
 Kimbaurer R, 182
 Kissinger P, 144
 Klausner JD, 294, 373, 411, 422
 Klein RS, 427
 Knapp JS, 668
 Knox J, 647
 Koblin BA, 406
 Kodagoda D, 277
 Koh D, 311
 Korenromp EL, 228
 Korte JE, 520
 Koskela P, 746
 Koutsky LA, 725
 Krekeler B, 100
 Krohn MA, 246
 Kumwenda NI, 366
 Kunene B, 32

L

Labbé A-C, 157
 Lafferty WE, 100
 Lafia E, 324
 Lagrange P, 698
 Lally MA, 752
 Lampe M, 253
 Langley C, 769
 Lassau F, 698
 Lau C-Y, 497
 Laumann EO, 689
 Lavori PW, 678
 Law M, 647
 Lawrence AM, 277
 Layde PM, 298
 Lecomte A, 624
 Legge D, 763
 Legros D, 376
 Lehrer RI, 514
 Leigh BC, 476
 Lemoine AL, 150
 Lengeler C, 715
 Lepkowski J, 13
 Levin D, 678
 Levine WC, 271, 769, 834
 Leyden WA, 678
 Liau A, 387
 Liomba GN, 366
 Lipsitch M, 399, 608
 Litchfield B, 144
 Little F, 239
 Liu H, 335
 Li X, 335
 Li Y, 1
 Lowndes CM, 324
 Luk YK, 360
 Lupiwa T, 265, 775
 Lystad A, 222

M

MacNevin R, 752
 Ma E, 335
 Maher JE, 38
 Makki HA, 73
 Malotte CK, 92
 Manalo R, 606
 Manhart LE, 133, 725
 Mann J, 344, 811
 Manos MM, 182, 678
 Maravi ME, 491
 Markakis D, 366
 Marmor M, 406
 Márquez CM, 792
 Martin DH, 486
 Martin IE, 780
 Mason D, 216
 Massad S, 427
 Massari V, 319
 Mathews C, 239
 Matson SC, 331
 Matter HC, 715
 Mayer K, 288, 406
 Mayhugh B, 491
 McGee ZA, 674
 McIlhane J, 811
 McKee KT Jr, 1
 Mehta SD, 83
 Mekonnen Y, 175
 Melzani G, 121
 Mendonça AP, 157
 Menzies IB, 73
 Mercier MM, 92
 Mertz KJ, 271, 834
 Mgone CS, 265, 775
 Mickey T, 372
 Mihret W, 175
 Miller HG, 588
 Miller P, 647
 Miller WC, 588
 Milligan GN, 597
 Millstein SG, 756
 Milord F, 157
 Minkoff H, 427
 Mirza H, 606
 Modarress KJ, 576
 Moench TR, 288, 655
 Morel P, 698
 Morency P, 157
 Mori G, 121
 Morineau G, 624
 Moriuchi H, 308
 Moriuchi M, 308
 Morse S, 253
 Moses AE, 483
 Moses S, 840
 Moulton LH, 201
 Muderspach L, 427
 Mukenge-Tshibaka L, 324
 Muliawan P, 50
 Mullick S, 32
 Muñoz A, 427
 Murrill CS, 73
 Mwai C, 106
 Mwatha A, 406
 Myer L, 239

N

Narvarte G, 510
 Ndinya-Achola J, 106
 Ndjomou J, 637
 Ndlovu J, 568

Neal SW, 668
 Newton ER, 520
 Ng L-K, 780
 Nicholson TL, 789
 Nilsen Ø, 222
 Noll WW, 628
 Norén L, 379
 Norman LR, 126
 Nyamukapa CA, 568
 Nyankiye E, 637

O

O'Brien ME, 144
 Oh MK, 20, 144, 387, 503
 Okuni T, 79
 Olcén P, 25
 Ondiege MY, 444
 Opal S, 606
 Orlander H, 253, 259
 Osato K, 79

P

Paget WJ, 715
 Palefsky J, 427
 Pang M, 514
 Passey ME, 265
 Patton DL, 581
 Payne WJ, 576
 Peipert JF, 288
 Pépin J, 157
 Perdue ST, 520
 Peterman TA, 38, 530
 Peter W, 265
 Petoumenos K, 647
 Petros B, 175
 Petzoldt D, 533
 Pick N, 483
 Pierzchalski JL, 331
 Piessens E, 427
 Pinkerton SD, 298
 Piper JM, 520
 Potterat JJ, 806
 Powers T, 1
 Prazuck T, 624
 Pugatch D, 752

Q

Qadadri B, 763
 Quan VM, 201
 Quinn TC, 1, 83
 Qureshi AK, 497

R

Rabe LK, 581
 Ramjee G, 44, 721
 Raymond M, 628
 Reece A, 597
 Reed BD, 50
 Rees H, 32
 Remien RH, 465
 Retel O, 319
 Reunala T, 746
 Rezza G, 665
 Rietmeijer CA, 65
 Rinke De Wit TF, 175
 Risser JMH, 391
 Risser WL, 391
 Ritzler E, 715
 Robinson NJ, 228
 Rodriguez V, 792
 Rogers SM, 588
 Rothenberg R, 463, 806
 Rothman RE, 83

Röttingen J-A, 818
 Russell DM, 265
 Ryan C, 559

S

Samalvides F, 510
 Sanchez C, 559
 Sanchez J, 559
 Sanders E, 175
 Sanders SA, 552
 Sawatzky P, 780
 Schiffman M, 182
 Scholl DT, 150
 Scholle SH, 246
 Schultz AJ, 668
 Schuman P, 427
 Schwebke JR, 59, 271
 Scott DR, 182
 Seas CR, 510
 Sednaoui P, 376
 Semmekrot BA, 710
 Shah KV, 427
 Shain RN, 520
 Shane SM, 150
 Shapiro S, 678
 Sherman ME, 182
 Shete PB, 655
 Shields T, 182
 Shlay JC, 491
 Silins I, 207
 Silveira MF, 536
 Silverberg MJ, 427
 Sionéan C, 20, 503
 Sirivongrangson P, 668
 Siwerth B-M, 379
 Smith BS, 486
 Smith C, 406
 Smith K, 486
 Sohn W, 13
 Spinola SM, 114
 Srugo I, 483
 St. Lawrence JS, 798
 Stall R, 643
 Stamm WE, 189, 253
 Stanberry LR, 597
 Steegers EAP, 710
 Steiner MJ, 168
 Steketee RW, 38
 Stephens J, 486
 Stephens RS, 789
 Stine C, 344, 811
 Stoner BP, 453
 Stürchler D, 715
 Sturm AW, 721
 Suchland RJ, 189
 Suligoi B, 665
 Sundby J, 828
 Sun H, 242
 Su X, 242
 Sweeney YTC, 581
 Swenson P, 253
 Swiss Sentinel Surveillance Network of Gynecologists, 715
 Switzer GE, 246
 Sylvan SPE, 379

T

Tabrizi SN, 647
 Taffa N, 828
 Taha TE, 366
 Tan Y, 212

Tao G. 703
 Tatara K. 79
 Tedeschi RM. 207
 Temmerman M. 106
 Tiveljung A. 379
 Tomasi E. 536
 Torian LV. 73
 Totten PA. 559
 Trees DL. 668
 Trent M. 397
 Tschann J. 756
 Tsegaye A. 175
 Tulloch SD. 271
 Turner CF. 588
 Turner KR. 422

U

Uche C. 126
 Unemo M. 25
 Uribasterra P. 112

V

Vaalasti A. 746
 Van Bemmelen R. 65
 van der Meijden WI. 710
 Van Dyck E. 324
 van Laere M. 710
 Van Royen P. 426
 Varghese B. 38
 Varkevisser CM. 444
 Verhoeven V. 426
 Vessey J. 344
 Vexiau-Robert D. 353
 Victoria CG. 536
 Voeten HACM. 444
 Voight RA. 834
 Volpi A. 665
 Volquez C. 559
 Von Krogh G. 379

W

Wagar EA. 514
 Walsh C. 542

Walsh CM. 703
 Walton P. 216
 Wang LY. 737
 Wang Q. 242
 Watts H. 427
 Weel JF. 710
 Weisfuse IB. 73
 Weiss HL. 59
 Weiss JB. 559
 Whaley KJ. 655
 Whittington WLH. 144, 189, 453
 Wiesenfeld HC. 112, 246
 Williams KM. 387
 Williams SP. 92
 Willis DE. 576
 Wilson SR. 678
 Wingood GM. 20, 387, 503
 Wirawan DN. 50
 Wolday D. 175
 Wolfe R. 50
 Wong EH. 422
 Wong ML. 311

Woodward C. 216
 Wu Z. 212

Y

Yarber WL. 552
 Yasin B. 514
 Yeka W. 775
 Ye S. 242
 Yin Y. 242, 335
 Youm Y. 689

Z

Zamborsky T. 246
 Zbinden R. 715
 Zenilman JM. 83, 201, 588
 Zerboni R. 665
 Zhang L. 212
 Zhuwau T. 568
 Zimmermann T. 533
 Zwahlen M. 715

STATEMENT OF OWNERSHIP MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685) 1. Publication Title: SEXUALLY TRANSMITTED DISEASES 2. Publication no.: 0148-5717 3. Filing date: 10-01-01. 4. Frequency of issue: Monthly 5. No. of issues published annually: 12; 6. Annual subscription price: \$216.00 7. Complete mailing address of known office of publication: Lippincott Williams & Wilkins, 16522 Hunters Green Parkway, Hagerstown, MD 21740-2116. 8. Complete mailing address of the headquarters of general business offices of the publisher: 530 Walnut Street, Philadelphia, PA 19106. 9. Full names and complete mailing address of publisher, editor, and managing editor: Publisher: Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Editor: Julius Schachter, PhD, Room 416/Bldg. #30, San Francisco General Hospital, 1001 Potrero Ave., San Francisco, CA 94110; Managing Editor: Jeanne Moncada, Room 416/Bldg. #30, San Francisco General Hospital, 1001 Potrero Ave., San Francisco, CA 94110. 10. Owner: American Sexually Transmitted Diseases Association, c/o: Denver Public Health, 605 Bannock Street, Denver, CO 80204. 11. Known bondholders, mortgagees, and other security holders owning or holding 1% or more of total amount of bonds, mortgages, or other securities: None. 12. Purpose, function, and nonprofit status: Has not changed during preceding 12 months. 13. Publication Name: SEXUALLY TRANSMITTED DISEASES 14. Issue Date for circulation data: Volume 28, Issue 8. 15. Extent and nature of circulation: Average number of copies each issue during preceding 12 months: (a) Total No. copies (Net Press Run), 1,892. (b) Paid and/or requested circulation: (1) Paid/requested outside-county mail subscriptions stated on form 3541. (Include advertiser's proof and exchange copies), 819; (2) Paid in-county subscriptions (include advertiser's proof and exchange copies), N/A; (3) Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution, 449; (4) Other classes mailed through the USPS, N/A. (c) Total paid and/or requested circulation (sum of 15b (1), (2), (3), and (4)), 1,253. (d) Free distribution by mail (samples, complimentary, and other free). (1) Outside-county as stated on form 3541, 70; (2) In country as stated on form 3541, N/A; (3) Other classes mailed through the USPS, N/A. (e) Free distribution outside the mail (carriers or other means), 45. (f) Total free distribution (sum of 15d and 15e), 115. (g) Total distribution (Sum of 15c and 15f), 1,368. (h) Copies not distributed, 524. (i) Total (sum of 15g and h), 1,892. (j) Percent paid and/or requested circulation (15c divided by 15g times 100), 91.59%. No. copies of single issue published nearest to filing date: (a) Total no. copies (Net Press Run), 1,950. (b) Paid and/or requested circulation: (1) Paid/requested outside-county mail subscriptions stated on form 3541. (Include advertiser's proof and exchange copies), 820; (2) Paid in-county subscriptions (include advertiser's proof and exchange copies), N/A; (3) Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution, 433; (4) Other classes mailed through the USPS, N/A. (c) Total paid and/or requested circulation (sum of 15b (1), (2), (3), and (4)), 1,253. (d) Free distribution by mail (samples, complimentary, and other free). (1) Outside-county as stated on form 3541, 41; (2) In-county as stated on form 3541, N/A; (3) Other classes mailed through the USPS, N/A. (e) Free distribution outside the mail (carriers or other means), 17. (f) Total free distribution (sum of 15d and 15e), 58. (g) Total distribution (Sum of 15c and 15f), 1,311. (h) Copies not distributed, 639. (i) Total (sum of 15g and h), 1,950. (j) Percent paid and/or requested circulation (15c divided by 15g x 100), 95.58%. 16. This Statement of Ownership will be printed in volume 28, issue 12 of this publication. 17. I certify that the statements made by me above are correct and complete. Jeffrey Brown, Manager, Periodical Operations

INDEX OF SUBJECTS

- A**
- Abscess, tuboovarian, *S. pyogenes*, 606
- Adolescents
- Chinese, premarital sex among, 212
- chlamydial infection in
- pubic lice as predictor of, 331
- screening for
- in high schools, 373, 737
- in Sweden, 379
- condom use by
- errors and problems in, 552
- perception of risk for STDs and, 756
- female
- African American
- marijuana use and STD infection in, 387
- with older partners, sexual behavior of, 20
- STD history and current risk behavior in, 503
- with older partners
- recurrent chlamydial infection and, 133
- risk behaviors of, 20
- gonorrhea in, screening for, in high schools, 373, 737
- incarcerated
- initial screening of, 834
- pelvic inflammatory disease in, 391
- knowledge of STDs of, 436
- male, STD prevalence and determinants of, in Jamaica, 126
- risk behaviors of, gonorrhea and chlamydia prevalence and, in Ethiopia, 828
- sexual mixing, bridging and concurrency in, 13, 133
- Africa
- adolescent risk behaviors in, gonorrhea and chlamydia prevalence and, 828
- antenatal syphilis screening in, 32
- genital herpes in, behavioral change and, 228
- HIV infection in, prevalence of and risk factors for, 366
- HSV-2 seropositivity in, 175, 537
- pregnancy outcome in syphilis/HIV infection in, 157
- sex workers in
- cervicitis in, syndromic vs. laboratory diagnosis of, 324
- characteristics of clients of, 444
- HIV-positive, STD incidence in, 721
- truck drivers in, HIV prevalence among, 44
- use of free condoms in, 239
- African Americans, female
- adolescent
- marijuana use and STD infection in, 387
- with older partners, sexual behavior of, 20
- STD history and current risk behavior in, 503
- douching practices of, microbicide testing and, 406
- Age, of sexual partners
- adolescent sexual mixing patterns and, 13
- black female adolescent risk behaviors and, 20
- recurrent chlamydial infection and, 133
- Alcohol use/abuse. *See also* Substance use/abuse
- condom use and, 476
- Anorectal chlamydial infection, in male bi/homosexuals, epidemiology of, 189
- Antimicrobials
- for chlamydial infection, efficacy and toxicity tests for, 655
- detergent-based vs. sulfated polymer-based, vaginal inflammation with, 597
- N. gonorrhoeae* resistance to
- in Canada, 780
- in China, 242
- in Thailand, 668
- quality control for, in Myanmar, 624
- rectal application of, 581
- trials of, douching and, 406
- vaginal, microflora changes with, 288
- Army recruits, female, chlamydia screening for, hospitalization rates and, 1
- Arrestees. *See also* Incarcerated persons
- syphilis screening in, 150
- Azithromycin
- vs. benzathine penicillin G, for syphilis, 486
- directly observed treatment with, in homeless woman, 372 (letter)
- vs. doxycycline, for chlamydial infection, 497
- B**
- Bacterial vaginosis, cervicitis and, 59
- Bahamas, crack cocaine epidemics in, STD prevalence and, 253, 259
- Bali, sex workers in, STD/HIV prevention programs for, 50
- Barrier contraceptives. *See also* Condoms
- in single vs. dual contraceptive approach, 168
- Behavioral interventions, success of, 520, 530 (editorial)
- Benin, sex workers in, syndromic vs. laboratory diagnosis of cervicitis in, 324
- Benzathine penicillin G, vs. azithromycin, for syphilis, 486
- Bias, social desirability
- reduction of, 568
- in surveys of male-to-male sexual activity, 643
- Bisexuals
- female, syphilis transmission in, 119
- male
- anorectal chlamydia/gonococcal infections in, epidemiology of, 189
- gonorrhea/chlamydia screening for, at entertainment venues, 216
- HIV infection in, racial disparities in, 73
- survey-based estimation of, 643
- syphilis outbreak in, rapid response to, 277, 285 (editorial)
- urethritis in, in France, 319
- Blacks. *See* African Americans
- Brazil, risk behaviors of urban women in, 536
- Bridging partners, adolescent, 13
- BufferGel
- for chlamydial infection, efficacy and toxicity tests for, 655
- microflora changes with, 288
- C**
- Cameroon, antibody to HSV-2 in, 537
- Canada
- ciprofloxacin-resistant *N. gonorrhoeae* in, 780
- physician compliance with screening/treatment guidelines in, 840
- Cancer, cervical, laser therapy for, lymphangioma circumscriptum of vulva after, 533
- Centers for Disease Control and Prevention (CDC)
- 1994 HIV guidelines of, conformation to, 417
- STD Treatment Guidelines of, need for revision of, 674 (editorial)
- Cervical cancer, laser therapy for, lymphangioma circumscriptum of vulva after, 533
- Cervical neoplasia, prevention of, condom use and, 725
- Cervical warts, relapse of, in HIV infection, 121
- Cervicitis
- bacterial vaginosis and, 59
- Mycoplasma genitalium* infection and, in French STD clinic attendees, 353
- in sex workers, syndromic vs. laboratory diagnosis of, in Benin, 324
- Cervicovaginal washings, from STD clinic attendees, HPV types in, 763
- Chancroid, in Dominican Republic and Peru, 559
- China
- drug-resistant *N. gonorrhoeae* in, 242
- premarital sex among university students in, 212
- risk factors for STDs and casual sex in STD clinic attendees in, 360
- STD stigmatization in, 355
- Chlamydial infection
- adolescent risk behaviors and, in Ethiopia, 828
- in adolescents, pubic lice as predictor of, 331
- anorectal, in male bi/homosexuals, epidemiology of, 189
- azithromycin vs. doxycycline for, 497
- clinic resource allocation for, 703

- with gonococcal infection, dual treatment vs. testing for, cost effectiveness of, 542
- incidence and repeat infection rates for, in STD clinic attendees, 65
- as marker for HIV incidence, in prevention trials, 298
- microbicides for, efficacy and toxicity tests for, 655
- persistent, PCR detection of, 196
- recurrent, in adolescents with older partners, 144
- in rural women, in Papua New Guinea, 775
- screening for
- in emergency departments, cost effectiveness of, 83
 - on entry into correctional facilities, 834
 - in female Army recruits, hospitalization rates and, 1
 - in high schools, 373
 - cost effectiveness of, 737
 - home based, 294
 - in jailed women, 271
 - in male bi/homosexuals, at entertainment venues, 216
 - in STD clinic attendees, 65
 - in Sweden, 379
 - urine-based, in Sweden, 379
- self-reported vs. NAAT-identified, risk behaviors and, 588
- self- vs. practitioner-collected specimens for, 647
- sensitivity of national laboratory reports for, in Switzerland, 715
- in sex workers
- in Papua New Guinea, 265
 - syndromic vs. laboratory diagnosis of, in Benin, 324
- specimen collection for PCR in, lubricant use and, 112
- vaginal pH and, 514
- Chlamydia trachomatis*, self- vs. practitioner-collected specimens of, 647
- Chlorhexidine digluconate, for chlamydial infection, efficacy and toxicity tests for, 655
- Ciprofloxacin, *N gonorrhoeae* resistance to
- in Canada, 780
 - in China, 242
 - in Thailand, 668
- Clinical trials
- microbicide, douching and, 406
 - prevention, STD incidence as marker for HIV incidence in, 298
- Clinic attendees. *See* Primary care recipients; Sexually transmitted disease clinic attendees
- CO₂ laser therapy, for cervical cancer, lymphangioma circumscriptum of vulva after, 533
- Cocaine. *See also* Substance use/abuse
- lymphogranuloma venereum prevalence and, in Bahamas, 253, 259
 - STD prevalence and, in Bahamas, 253, 259
- College students. *See also* Adolescents
- Chinese, premarital sex among, 212
 - condom use errors and problems in, 552
- Concurrency, 133
- among adolescents, 13
 - patterns of, 453, 463 (editorial)
- Condoms
- effectiveness of, 344, 350 (editorial)
 - in single vs. dual contraceptive approach, 168
 - use of. *See also* Risk behaviors
 - by adolescents
 - errors and problems in, 552
 - perception of risk for STDs and, 756 - alcohol use and, 476
 - among Chinese STD clinic attendees, 360
 - effectiveness of, 811
 - errors and problems in, among university students, 552
 - with free distribution, in South Africa, 239
 - in HIV risk reduction, 38
 - interventions to increase, 520, 530 (editorial)
 - intimate partner violence and, 411
 - by Kenyan sex worker clients, 444
 - marijuana use by black female adolescents and, 387
 - in oral sex, 311
 - in prevention of HPV infection, 725
 - by sex workers in Papua New Guinea, 265
- Condylocum acuminatum
- in HIV infection, 121, 427
 - in immunodeficiency states, 121, 427
 - prevention of, condom use and, 725
 - relapse of, in HIV infection, 121
- Contraception. *See also* Condoms
- IUD for, group A streptococcal infection and, 483
 - one- vs. two-method approach in, 168
- Crack cocaine. *See also* Substance use/abuse
- STD prevalence and, in Bahamas, 253, 259
- ### D
- Data collection, social desirability bias in, 568, 643
- Developing countries. *See also specific countries*
- adolescent risk behaviors in, gonorrhea and chlamydia prevalence and, 828
 - antenatal syphilis screening in, 32
 - antibody to HSV-2 in, 537
 - antimicrobial quality control in, 624
 - crack cocaine epidemics in, lymphogranuloma venereum prevalence and, 253, 259
 - data collection in, social desirability bias in, 568
 - genital herpes in, behavioral change and, 228
 - genital ulcer disease in, 559
 - HIV infection in, prevalence of and risk factors for, 366
 - HSV-2 seropositivity in, 175
 - pregnancy outcome in syphilis/HIV infection in, 157
 - primary care patients in, health-seeking and sexual behaviors of, 106
 - sex workers in
 - cervicitis in, syndromic vs. laboratory diagnosis of, 324
 - characteristics of clients of, 444
 - HIV-positive, STD incidence in, 265, 721
 - treatment barriers for female STDs in, 201
 - truck drivers in, HIV prevalence among, 44
- Domestic violence, risk behaviors and, 411
- Dominican Republic, genital ulcer disease in, 559
- Douching
- interventions to reduce, 520, 530 (editorial)
 - by women at high risk for HIV infection, 406
- Doxycycline, vs. azithromycin, for chlamydial infection, 497
- Drug abuse. *See* Substance use/abuse
- Drug resistance, of *N gonorrhoeae*
- in Canada, 780
 - in China, 242
 - in Kyrgyzstan, 376
 - in Thailand, 668
- ### E
- Editorials, 285, 350, 463, 472, 530, 674, 789 (editorial)
- Entertainment venues, screening for gonorrhea/chlamydia in male bi/homosexuals at, 216
- Epidemiologic studies, genotyping in, 379
- Epidemiology
- clustered STD seropositivity and, 207
 - social network effects and, 689
- Ethiopia
- adolescent risk behaviors in, gonorrhea and chlamydia prevalence and, 828
 - HSV-2 seropositivity in, 175
- External genital warts
- in HIV infection, 121, 427
 - in immunodeficiency states, 121, 427
 - prevention of, condom use and, 725
 - relapse of, in HIV infection, 121
- ### F
- Family planning programs, resource allocation for chlamydial infection in, 703
- Fetal demise, syphilis/HIV infection and, 157
- Finland, imported syphilis epidemics in, 746
- France, *Mycoplasma genitalium* infection in, in STD clinic attendees, 353
- Freebasing, STD prevalence and, in Bahamas, 253, 259

G

- Gay men. *See* Male-to-male sexual behavior
- Gene expression analysis, microarray, 789 (editorial)
- Genital herpes
- in Africa, behavioral change and, 228
 - cost projections for, 608
 - in Dominican Republic and Peru, 559
 - in HIV infection, prevalence and determinants of, in Italy, 665
 - prevalence of, 608
 - in Cameroon, 537
 - prevention of, condom use and, 725
 - serodiagnostic test for, in pregnant women and their partners, 399
 - seroprevalence of, in Dutch pregnant women, 710
 - in sub-Saharan Africa, behavioral changes and, 228
 - type-specific serologic testing for, 422
 - in vitro reactivation of HIV infection in, 308
- Genital ulcer disease. *See also specific etiologies*
- crack cocaine use and, in Bahamas, 253, 259
 - in Dominican Republic and Peru, 559
- Genital warts
- in HIV infection, 121, 427
 - in immunodeficiency states, 121, 427
 - prevention of, condom use and, 725
 - relapse of, in HIV infection, 121
- Genotyping, in epidemiologic studies, 379
- GenProbe PACE 2 tests, hybrid capture 2 CT/GC DNA tests and, using same urethral swab, 576
- Gonococcal cervicitis, in sex workers, syndromic vs. laboratory diagnosis of, in Benin, 324
- Gonorrhea
- adolescent risk behaviors and, in Ethiopia, 828
 - asymptomatic chlamydial infection in, dual treatment vs. testing for, cost effectiveness of, 542
 - drug-resistant, in China, 242
 - epidemiologic analysis of, pulsed-field gel electrophoresis in, 25
 - in male bi/homosexuals, epidemiology of, 189
 - as marker for HIV incidence, in prevention trials, 298
 - pharyngeal, condom use and, 311
 - rising incidence of, in French males, 319
 - in rural women, in Papua New Guinea, 775
 - screening for
 - on entry into correctional facilities, 834
 - in high schools, 373
 - cost effectiveness of, 737
 - home based, 294
 - in jailed women, 271
 - in male bi/homosexuals, at entertainment venues, 216
 - self-reported vs. NAAT-identified, risk behaviors and, 588
 - self- vs. practitioner-collected specimens for, 647
 - in sex workers
 - in Papua New Guinea, 265
 - syndromic vs. laboratory diagnosis of, in Benin, 324
 - surveillance programs for, 806 (editorial)
- Group A streptococcal infection, associated with IUD and oral sex, 483
- Guinea-Bissau, pregnancy outcome in syphilis/HIV infection in, 157

H

- Haemophilus ducreyi* infection
- in Dominican Republic and Peru, 559
 - pustule formation in, in men vs. women, 114
- Healthcare utilization
- by primary care patients, in Kenya, 106
 - after STD diagnosis, in women, 678
- Hepatitis B, as marker for HIV incidence, in prevention trials, 298
- Herpes simplex virus, type 2
- seropositivity for
 - in Cameroon, 537
 - in Ethiopia, 175
 - type-specific serologic testing for, 422
- Herpes simplex virus infection
- in Dominican Republic and Peru, 559
 - in HIV infection, prevalence and determinants of, in Italy, 665

- serodiagnostic test for, in pregnant women and their partners, 399
 - seroprevalence of, in Dutch pregnant women, 710
 - in sub-Saharan Africa, behavioral changes and, 228
 - type 2
 - prevalence and cost projections for, 608
 - prevalence of, in Cameroon, 537
 - in vitro reactivation of HIV infection in, 308
- High schools, chlamydia/gonorrhea screening in, 373
- cost-effectiveness of, 737
- Hispanics, douching practices of, microbicide testing and, 406
- Home-based screening, for chlamydia/gonorrhea, 294
- Homeless patient, syphilis in, directly observed azithromycin treatment for, 372 (letter)
- Homosexuals
- female, syphilis transmission in, 119
 - male
 - anorectal chlamydia/gonococcal infections in, epidemiology of, 189
 - gonorrhea/chlamydia screening for, at entertainment venues, 216
 - HIV infection in, racial disparities in, 73
 - survey-based estimation of, 643
 - syphilis outbreak in, rapid response to, 277, 285 (editorial)
 - urethritis in, in France, 319
- Human herpesvirus 8, seroprevalence of, in French STD clinic attendees, 698
- Human immunodeficiency virus infection
- crack cocaine use and, in Bahamas, 253, 259
 - epidemic, in Norway, 222
 - genital herpes in, prevalence and determinants of, in Italy, 665
 - genital warts and, 121, 427
 - incidence of, STD incidence as marker for, in prevention trials, 298
 - 1994 CDC guidelines for, conformation to, 417
 - physician compliance with screening/treatment guidelines for, in Canada, 840
 - pregnancy outcome in, 157
 - prevalence of and risk factors for, in Malawi, 366
 - prevention programs for, in Balinese sex workers, 38
 - risk reduction for, 38
 - in sex workers, in Papua New Guinea, 265
 - in South African truck drivers, truck drivers in, 44
 - STD incidence in, in South African sex workers, 721
 - transmission of, within sexual partnership, 818
 - in vitro reactivation of, in HSV infection, 308
- Human papillomavirus, types of, in cervicovaginal washings from STD clinic attendees, 763
- Human papillomavirus infection
- HIV infection and immunodeficiency and, 427
 - prevention of, condom use and, 725
 - tampon sampling for, 628
 - type 16, seropositivity for, sexual behavior and, 182
- Hybrid capture 2 CT/GC DNA tests, and GenProbe PACE 2 tests, using same urethral swab, 576

I

- Immunodeficiency. *See also* Human immunodeficiency virus infection
- genital warts and, 427
- Incarcerated persons
- female
 - adolescent, pelvic inflammatory disease in, 391
 - chlamydia/gonorrhea screening in, 271
 - initial screening of, 834
 - syphilis screening in, 150
- Integrated information systems, in prediction of syphilis outbreaks, 6
- Intimate partner violence, risk behaviors and, 411
- Intrauterine device, group A streptococcal infection and, 483
- Italy, HSV-2 infection in HIV infection in, prevalence and determinants of, 665

J

- Jail population. *See* Incarcerated persons
- Jamaica, STD prevalence and determinants in, in young males, 126
- Japan, vaginal vs. nonvaginal sex workers in, STD risk reduction for, 79

K

- Kenya
 primary care patients in, health-seeking and sexual behaviors of, 106
 sex workers in, characteristics of clients of, 444
 Kyrgyzstan, *N gonorrhoeae* isolates from, in vitro susceptibility of, 376

L

- Lactobacillus* colonization, vaginal microbicide and, 288
 Laser therapy, for cervical cancer, lymphangioma circumscriptum of vulva after, 533
 Latin America
 genital ulcer disease in, 559
 travelers to, sexual behavior of, 510
 Latinas, douching practices of, microbicide testing and, 406
 Lesbians, syphilis transmission in, 119
 Less-developed countries. *See* Developing countries
 Letters, 372, 426
 Lice, pubic, as chlamydial infection predictor, in adolescents, 331
 Lubricants, specimen collection for *C trachomatis* PCR and, 112
 Lymphangioma circumscriptum of vulva, after laser therapy for cervical cancer, 533
 Lymphogranuloma venereum
 crack cocaine use and, in Bahamas, 253, 259
 in Dominican Republic and Peru, 559

M

- Mail-returned specimens, in home-based screening, 294
 Malawi, HIV infection in, prevalence of and risk factors for, 366
 Male-to-male sexual behavior
 anorectal chlamydia/gonococcal infections in, epidemiology of, 189
 gonorrhea/chlamydia screening for, at entertainment venues, 216
 HIV infection in, racial disparities in, 73
 survey-based estimation of, 643
 syphilis outbreak in, rapid response to, in Los Angeles, 277, 285 (editorial)
 urethritis in, in France, 319
 Marijuana. *See also* Substance use/abuse
 sexual risk behaviors and, in black female adolescents, 387
 Medicaid-enrolled STD clinic attendees, underidentification of, 100
 Metronidazole, for bacterial vaginosis-related cervicitis, 59
 Microarray technology, 789 (editorial)
 Microbicides
 for chlamydial infection, efficacy and toxicity tests for, 655
 detergent-based vs. sulfated polymer-based, vaginal inflammation with, 597
N gonorrhoeae resistance to
 in Canada, 780
 in China, 242
 in Thailand, 668
 quality control for, in Myanmar, 624
 rectal application of, 581
 trials of, douching and, 406
 vaginal, microflora changes with, 288
 Microflora, changes in, with vaginal microbicide use, 288
 Military recruits, female, chlamydia screening for, hospitalization rates and, 1
 Myanmar, antimicrobial quality control in, 624
Mycoplasma genitalium infection, in French STD clinic attendees, 353

N

- Neisseria gonorrhoeae*. *See also* Gonorrhea
 drug-resistant
 in Canada, 780
 in China, 242
 in Kyrgyzstan, 376
 in Thailand, 668
 self- vs. practitioner-collected specimens of, 647
 tetracycline-resistant, novel Tet M determinant and, 792
 in vitro susceptibility of isolates from Kyrgyzstan, 376
 Neonatal herpes, prevention of, maternal serodiagnostic testing for, 399
 Netherlands, HSV-1/2 seroprevalence in, among pregnant women, 710
 Nongonococcal urethritis, rising incidence of, in French males, 319

Nonoxynol-9

- for chlamydial infection, efficacy and toxicity tests for, 655
 rectal application of, 581
 Norway, HIV epidemic in, 222

O

- Older partners, of female adolescents
 recurrent chlamydial infection and, 133
 risk behaviors and, 20
 Oral sex
 condom use in, 311
 female-to-female, syphilis transmission via, 119
 group A streptococcal infection and, 483

P

- Papua New Guinea
 gonorrhea/STD prevalence in, in rural women, 775
 HIV/STD prevalence in, in sex workers, 265
 Partner concurrency, 133
 among adolescents, 13
 patterns of, 453, 463 (editorial)
 Partner notification
 in China, 355
 client preferences for, 92
 by New York City STD clinic attendees, 465, 472 (editorial)
 Pelvic inflammatory disease
 in incarcerated adolescents, 391
Mycoplasma genitalium infection and, in French STD clinic attendees, 353
S pyogenes tuboovarian abscess in, 606
 treatment barriers for, in Vietnamese women, 201
 Penicillin
 vs. azithromycin, for syphilis, 486
N gonorrhoeae resistance to, in China, 242
 Peru, genital ulcer disease in, 559
 pH, vaginal, chlamydial infection and, 514
 Pharyngeal gonorrhea, condom use and, 311
Phthirus pubis infection, as chlamydial infection predictor, in adolescents, 331
 Physicians
 compliance of with screening/treatment guidelines, in Canada, 840
 primary care, attitudes of toward STDs, 246
 Polymerase chain reaction
 for *C trachomatis*, specimen collection for, lubricant use and, 112
 in persistent chlamydial infection, 196
 self- vs. practitioner-collected samples for, 647
 Pregnancy
 HSV infection in, serodiagnostic test for, 399
 HSV seroprevalence in, in Netherlands, 710
 outcome of, in syphilis/HIV infection, 157
 risk prediction for, among STD clinic attendees, 491
 Premarital sex, among Chinese university students, 212
 Prematurity, syphilis/HIV infection and, 157
 Prevention trials, STD incidence as marker for HIV incidence in, 298
 Preventive strategies, behavioral change vs. disease reduction due to, 520, 530 (editorial)
 Primary care physicians, attitudes of toward STDs, 246
 Primary care recipients, health-seeking and sexual behaviors of, in Kenya, 106
 Prisoners. *See* Incarcerated persons
 Prostitutes. *See* Sex workers
 Pubic lice, as chlamydial infection predictor, in adolescents, 331
 Pulsed-field gel electrophoresis, in epidemiologic study of *N gonorrhoeae*, 25

Q

- Quality control, microbicidal, in Myanmar, 624

R

- Race, HIV infection rates in male bisexuals/homosexuals and, 73
 Rectal application, of Nonoxynol-9, 581
 Rectal chlamydial infection, in male bi/homosexuals, epidemiology of, 189

- Reproductive tract infections, treatment barriers for, in Vietnamese women, 201
- Risk behaviors
- adolescent, 13, 20, 126, 133, 503, 828. *See also* Adolescents
 - alcohol use and, 476
 - of Chinese STD clinic attendees, 360
 - clustered STD seropositivity and, 207
 - gonorrhea and chlamydia prevalence and, in Ethiopia, 828
 - HPV 16 seropositivity and, 182
 - interventions for, behavioral change vs. disease reduction due to, 520, 530 (editorial)
 - intimate partner violence and, 411
 - marijuana use and, 387
 - of primary healthcare patients, 106
 - self-reported vs. NAAT-identified STDs and, 588
 - STD history and, in black adolescent females, 503
 - surveys of, social desirability bias in, 568
 - of urban Brazilian women, 536
 - of visitors to Peru, 510
 - of young male Jamaicans, 126
- Risk-reduction interventions, behavioral change vs. disease reduction due to, 520, 530 (editorial)
- Russia, substance use/abuse by sex workers in, 798
- S**
- Screening
- for chlamydial infection
 - in emergency departments, cost effectiveness of, 83
 - in female Army recruits, hospitalization rates and, 1
 - in high schools, 373
 - cost effectiveness of, 737
 - home based, 294
 - in jailed women, 271
 - in male bi/homosexuals, at entertainment venues, 216
 - in STD clinic attendees, 65
 - in Sweden, 379
 - urine-based, in Sweden, 379
 - on entry into correctional facilities, 834
 - for gonorrhea
 - in high schools, 373
 - cost effectiveness of, 737
 - home based, 294
 - in jailed women, 271
 - in male bi/homosexuals, at entertainment venues, 216
 - physician compliance with guidelines for, in Canada, 840
 - during short-term treatment for substance abuse, 752
 - for syphilis
 - antenatal, in South Africa, 32
 - in arrestees, 150
- Self-collected vaginal swabs, 426 (letter)
- Seroprevalence
- of HSV-2, in Africa, 175, 537
 - of human herpesvirus 8, in French STD clinic attendees, 698
 - of STDs, clustering of, 207
- Sex acts, choice of, for HIV risk reduction, 38
- Sex education
- condom use instruction in, 552
 - effectiveness of, 436
- Sex partners
- choice of, for HIV risk reduction, 38
 - concurrency of, 133
 - among adolescents, 13
 - patterns of, 453, 463 (editorial)
 - HIV transmission between, 818
 - older
 - recurrent chlamydial infection and, 133
 - risk behaviors and, 13, 20
- Sexual behavior
- adolescent, 13, 20, 126, 133, 503, 828. *See also* Adolescents
 - alcohol use and, 476
 - of Chinese STD clinic attendees, 360
 - clustered STD seropositivity and, 207
 - HPV 16 seropositivity and, 182
 - interventions for, behavioral change vs. disease reduction due to, 520, 530 (editorial)
 - intimate partner violence and, 411
 - male-to-male. *See* Male-to-male sexual behavior
 - marijuana use and, 387
 - partner age and, 13, 20
 - of primary healthcare patients, 106
 - STD history and, in black adolescent females, 503
 - surveys of, social desirability bias in, 568
 - of urban Brazilian women, 536
 - of visitors to Peru, 510
 - of young male Jamaicans, 126
- Sexually transmitted disease clinic attendees
- chlamydial infection in, incidence and repeat infection rates for, 65
 - HPV types in cervicovaginal washings from, 763
 - human herpesvirus 8 seroprevalence in, in France, 698
 - Medicaid-enrolled, underidentification of, 100
 - Mycoplasma genitalium* infection in, in France, 353
 - partner notification by, 465, 472 (editorial)
 - pregnancy risk prediction for, 491
 - risk factors for STDs and casual sex for, in China, 360
- Sexually transmitted disease programs, in developing countries, drug quality control for, 624
- Sexually transmitted diseases. *See also* specific diseases
- adolescent knowledge of, 435
 - complications of, healthcare utilization for, 678
 - in HIV-positive sex workers, in South Africa, 721
 - as marker for HIV incidence, in prevention trials, 298
 - newly diagnosed, healthcare utilization after, by women, 678
 - outbreaks of, prediction of, integrated information systems in, 6
 - prevalence and determinants of, in young Jamaican males, 126
 - prevention programs for, in Balinese sex workers, 38
 - risk factors for, in Chinese patients in Hong Kong, 360
 - screening for. *See* Screening
 - seropositivity for, clustering of, 207
 - in sex workers, in Papua New Guinea, 265
 - transmission of, social network effects on, 689
 - treatment barriers for, in Vietnamese women, 201
- Sexual mixing, among adolescents, 13
- Sex workers
- in Benin, cervicitis in, syndromic vs. laboratory diagnosis of, 324
 - condoms for oral sex for, 311
 - HIV-positive, STD incidence in
 - in Papua New Guinea, 265
 - in South Africa, 721
 - in Kenya, characteristics of clients of, 444
 - STD/HIV prevention programs for, in Bali, 50
 - substance use/abuse by, in Russia, 798
 - vaginal vs. nonvaginal, STD risk reduction for, in Japan, 79
- Small-for gestational infants, intrauterine syphilis/HIV infection and, 157
- Social desirability bias
- reduction of, 568
 - in surveys of male-to-male sexual activity, 643
- Social network effects, on STD transmission, 689
- Sodium dodecyl sulfate, for chlamydial infection, efficacy and toxicity tests for, 655
- Soldiers, female, chlamydia screening for, hospitalization rates and, 1
- South Africa
- antenatal syphilis screening in, 32
 - STD incidence in HIV-positive sex workers in, 721
 - truck drivers in, HIV prevalence among, 44
 - use of free condoms in, 239
- South America
- genital ulcer disease in, 559
 - travelers to, sexual behavior of, 510
- Specimen collection
- for *C. trachomatis* polymerase chain reaction, lubricant use and, 112
 - for hybrid capture 2 CT/GC DNA tests and GenProbe PACE 2 test, single urethral swab for, 576
 - self-performed, vs. practitioner-performed, for PCR, 647

- from tampons, for HPV infection, 628
- Specimen return, via U.S. mail, in home-based screening, 294
- Spontaneous abortion, syphilis/HIV infection and, 157
- Spousal abuse, risk behaviors and, 411
- Stigmatization, of male STD patients, in China, 355
- Stillbirth, syphilis/HIV infection and, 157
- Streptococcal infection, associated with IUD and oral sex, 483
- Streptococcus pyogenes* tuboovarian abscess, 606
- Students. *See also* Adolescents
 - high school, on-site chlamydia/gonorrhea screening for, 373
 - cost effectiveness of, 737
 - university
 - condom use errors and problems in, 552
 - premarital sex among, in China, 212
- Substance use/abuse
 - condom use and, 476
 - lymphogranuloma venereum prevalence and, in Bahamas, 253, 259
 - by Russian sex workers, 798
 - sexual risk behaviors and, in black female adolescents, 387
 - short-term treatment for, STD screening in, 752
 - STD prevalence and, in Bahamas, 253, 259
- Surveillance programs
 - for gonorrhea, 806 (editorial)
 - for syphilis, prevalence monitoring in, 769
- Surveys, social desirability bias in
 - in estimation of male-to-male sexual activity, 568
 - reduction of, 568
- Swabs
 - single urethral, hybrid capture 2 CT/GC DNA tests and GenProbe PACE 2 tests from, 576
 - vaginal, self-collected, 426 (letter)
 - vs. practitioner-collected, for PCR, 647
 - vs. tampon sampling, for HPV infection, 628
- Sweden, urine screening for *C. trachomatis* in, 379
- Switzerland, chlamydial infection in, sensitivity of national laboratory reports for, 715
- Syphilis
 - antenatal screening for, in South Africa, 32
 - azithromycin vs. benzathine penicillin G for, 486
 - in Dominican Republic and Peru, 559
 - female-to-female transmission of, 119
 - in homeless woman, directly observed azithromycin treatment for, 372 (letter)
 - imported epidemics of, in Finland, 746
 - as marker for HIV incidence, in prevention trials, 298
 - outbreak of
 - prediction of, integrated information systems in, 6
 - rapid response to, in Los Angeles, 277, 285 (editorial)
 - pregnancy outcome in, 157
 - in rural women, in Papua New Guinea, 775
 - screening for
 - in arrestees, 150
 - on entry into correctional facilities, 834
 - in sex workers, in Papua New Guinea, 265
 - surveillance programs for, prevalence monitoring in, 769
- T
 - Tampon sampling, for HPV infection, 628
 - Tet M determinant, in *N. gonorrhoeae* tetracycline resistance, 792
 - Tetracycline, *N. gonorrhoeae* resistance to
 - in China, 242
 - novel Tet M determinant in, 792
 - Thailand, ciprofloxacin-resistant *N. gonorrhoeae* in, 668
 - Third-world countries. *See* Developing countries
 - Toxic shock syndrome, associated with IUD and oral sex, 483
 - Travelers, to Peru, sexual behavior of, 510
 - Treatment delay, in China, 355
 - Trichomoniasis
 - in rural women, in Papua New Guinea, 775
 - self- vs. practitioner-collected specimens for, 647
 - in sex workers, in Papua New Guinea, 265
 - Tuboovarian abscess, *S. pyogenes*, 606
- U
 - University students. *See also* Adolescents
 - Chinese, premarital sex among, 212
 - condom use errors and problems in, 552
 - Urethral swabs, single, hybrid capture 2 CT/GC DNA tests and GenProbe PACE 2 tests from, 576
 - Urethritis, rising incidence of, in French males, 319
 - Urine-based screening, in female jail population, 271
 - Uruguay, *N. gonorrhoeae* tetracycline resistance in, novel Tet M determinant in, 792
- V
 - Vaginal inflammation, with detergent-based vs. sulfated polymer-based microbicides, 597
 - Vaginal microbicide, microflora changes with, 288
 - Vaginal pH, chlamydial infection and, 514
 - Vaginal swabs, self-collected, 426 (letter)
 - vs. practitioner-collected, for PCR, 647
 - vs. tampon sampling, for HPV infection, 628
 - Viet Nam, treatment barriers for female STDs in, 201
 - Violence, intimate partner, risk behaviors and, 411
 - Vulva, lymphangioma circumscriptum of, after laser therapy for cervical cancer, 533
- W
 - Warts
 - cervical, relapse of, in HIV infection, 121
 - genital
 - in HIV infection, 121
 - in immunodeficiency states, 121, 427
 - prevention of, condom use and, 725
 - relapse of, in HIV infection, 121